US Patent Issued to Ascendo Biotechnology on June 23 for "Selective targeting of the TREML1/MD2 interaction by small peptide or protein and its use for vaccine adjuvants" (Taiwanese Inventors)

ALEXANDRIA, Va., July 15 -- United States Patent no. 12,661,396, issued on June 23, was assigned to Ascendo Biotechnology Inc. (Grand Cayman, Cayman Islands).

"Selective targeting of the TREML1/MD2 interaction by small peptide or protein and its use for vaccine adjuvants" was invented by Yen-Ta Lu (Taipei, Taiwan), Chia-Ming Chang (Taipei, Taiwan), Ping-Yen Huang (Taipei, Taiwan) and I-Fang Tsai (Taipei, Taiwan).

According to the abstract* released by the U.S. Patent & Trademark Office: "A pharmaceutical composition for boosting an immune response contains TREM-like transcript-1 (TREML1) extracellular domain (ECD) or stalk polypeptide. The TREML1 ECD or stalk polypeptide is derived from human or mouse TREML1. The pharmaceutical compositio...